DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2014/0128399 A1 Abraham Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2014/0128399 A1 Abraham Et Al US 2014.0128399A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0128399 A1 Abraham et al. (43) Pub. Date: May 8, 2014 (54) METHODS AND COMPOSITIONS FOR Publication Classification TREATING URINARY TRACT INFECTIONS USINGAGENTS THAT MIMIC OR ELEVATE (51) Int. Cl. CYCLICAMP A613 L/53 (2006.01) A6II 45/06 (2006.01) (71) Applicant: DUKE UNIVERSITY, DURHAM, NC A613 L/4985 (2006.01) (US) A 6LX3/59 (2006.01) (52) U.S. Cl. (72) Inventors: Soman N. Abraham, Chapel Hill, NC CPC ............... A61 K3I/53 (2013.01); A61 K3I/519 (US); Brian L. Bishop. Durham, NC (2013.01); A61K 45/06 (2013.01); A61 K (US); Matthew J. Duncan, Duncan, SC 31/4985 (2013.01) (US); K. Ranga Rama Krishnan, USPC 514/243; 514/261.1: 514/252.16; 514/262.1; Chapel Hill, NC (US); Jeongmin Song, 514/250 Chapel Hill, NC (US); Guojie Li, (57) ABSTRACT Charlotte, NC (US); David W. Zaas, Methods and compositions are provided for treating a urinary Chapel Hill, NC (US) tract infection (UTI). The methods involve administering to a subject in need thereof a cAMP elevator or agent that mimics cAMP particularly a labdane diterpene such as forskolin or a (73) Assignee: DUKE UNIVERSITY, DURHAM, NC derivative or analog thereof in a therapeutically effective (US) amount to treat a UTI. The methods may further include administration of at least one cAMP elevator in combination (21) Appl. No.: 14/098,839 with one or more additional active compounds from other classes of therapeutic agents, such as antimicrobial agents or cholesterol lowering drugs. Compositions of the invention (22) Filed: Dec. 6, 2013 include pharmaceutical compositions and kits for treating a UTI in a subject in need thereof that include therapeutically Related U.S. Application Data effective amounts of at least two cAMP elevators, particularly where one of the cAMP elevators is a labdane diterpene such (63) Continuation of application No. 12/663,959, filed on as forskolin or a derivative oranalog thereof. In particular, the Sep. 21, 2010, now abandoned, filed as application No. compositions and kits may also include at least one cAMP PCT/US2008/066647 on Jun. 12, 2008. elevator in combination with one or more additional active (60) Provisional application No. 60/944,182, filed on Jun. compounds from other classes of therapeutic agents. Such as 15, 2007. antimicrobial agents or cholesterol lowering drugs. Patent Application Publication May 8, 2014 Sheet 1 of 19 US 2014/O128399 A1 Patent Application Publication May 8, 2014 Sheet 2 of 19 US 2014/O128399 A1 Figure 2 After alterest e 120% 8 3 100% e 80% 60% & 40% is 20% 0% Patent Application Publication May 8, 2014 Sheet 3 of 19 US 2014/O128399 A1 Figure 3 c 100% : 40% as 80% as O 3O% 3 60% 38 5 g a g 20% 3 40% E3 (s ; its c & 20% a: Ys 10% O% S O% Forskoln dibutyryl ionophore E. Col E. coli E. coli (100M) cAMP (1 M) - NC - H89 (1 mM) Patent Application Publication May 8, 2014 Sheet 4 of 19 US 2014/O128399 A1 Figure 4 the '9e anti-EE A1 merge transferrin-A483 merge's Patent Application Publication May 8, 2014 Sheet 5 of 19 US 2014/0128399 A1 Figure 5 a g 14.0% b. 3,500 3 120% as 3,000 s 100% s 2,500 is 80% is 2,000 60% 1,500 $ 40% 1,000 20% soo 0%. H v 0 24 48 72 96 i20 s'sNS s SSY S&SS Time after invasion (h) s s so MS S C 6% d ar 3g a 2.4% 3 is 10% & 1 R sis 8% gA. 6%4% S. ig 2% gs O%, S. &Sis S a es S S gy ca CS&S oSS8 Patent Application Publication May 8, 2014 Sheet 6 of 19 US 2014/O128399 A1 Figure 6 SO9. 12596 OO96 S. 25 Control Bafilomycin NHC NH4Cl (M) (OmM) (SOmM) Patent Application Publication May 8, 2014 Sheet 7 of 19 US 2014/0128399 A1 Figure 7 frner unon lufter C S 150% d 1509. t 8 i25% 125% s 8 g is 100% 100% s is 8 75% 75 60% Egg 50% g f is 25% 25% t O% -- O control Forskoir- Contro Forskoin- Salie Forskolin E. cf treated S.&retica treated Ecci S. enterica e 150% f 140% 25% g 23% i. re 100% to 85 OO%o is 80% 2 3. 739. 3: g s 3 60% S 50% & S. 40% 25% &. 2O's r O% O% Saline Forskoln S&tine Foskolin Salle ForSkoli Before treatment 8 after treatment Patent Application Publication May 8, 2014 Sheet 8 of 19 US 2014/O128399 A1 Patent Application Publication May 8, 2014 Sheet 9 of 19 US 2014/O128399 A1 OOOOOO OOOOO 1DOD) OOO OO O Bis gii; 1 3. : s ES: PFsk f Catheter FS AO2OOO 1653 Patent Application Publication May 8, 2014 Sheet 10 of 19 US 2014/O128399 A1 Figure 10 20 O 18O 16O. 40 1 2 O 100 Untreated TLR4 ligand (LPS) Patent Application Publication May 8, 2014 Sheet 11 of 19 US 2014/0128399 A1 Figure 11 Forskoi W Caffeine s e s s Untreated OOM forsko in 1 nM Caffeine O ty f) Skoli nM Caffeine Patent Application Publication May 8, 2014 Sheet 12 of 19 US 2014/O128399 A1 Figure 12 Forskolin wi Papa verine se 5 C o s m s se Se: s te & g 5 o V. o war Ve Patent Application Publication May 8, 2014 Sheet 13 of 19 US 2014/0128399 A1 Figure 13 Forsko in W. B. VX Untreated 10DuM forskolin 500 unt BMX forskors) LM BMX Patent Application Publication May 8, 2014 Sheet 14 of 19 US 2014/0128399 A1 Figure 14 Forskolin W. ENA Untreated 1 OOM forskoir 2 UM EHNA ftorsko in 200 M E-NA, Patent Application Publication May 8, 2014 Sheet 15 of 19 US 2014/0128399 A1 Figure 15 Forskolin wi Rolipram Untreated 1 OOM forskolin 40Ould rolipram Ouwford 400u M rol Patent Application Publication May 8, 2014 Sheet 16 of 19 US 2014/O128399 A1 Figure 16 Forskolin w Zaprina st s ads s s Untreated y forsko Zapirast firsgirlf?0 M Zaprinast Patent Application Publication May 8, 2014 Sheet 17 of 19 US 2014/0128399 A1 Figure 17 Ciliostamide-POE3 inhibitor s 3. - - - - - - - - - - - - - - - --------------------------------- - Patent Application Publication May 8, 2014 Sheet 18 of 19 US 2014/0128399 A1 Figure 18 PMA-PKC activator 2 Untreated Patent Application Publication May 8, 2014 Sheet 19 of 19 US 2014/O128399 A1 Figure 19 hs wu O 9 O 9. (vs. w 9 g SS le () O wVCoy 8 X O) s () US 2014/O128399 A1 May 8, 2014 METHODS AND COMPOSITIONS FOR activators, including, for example, labdane diterpenes (par TREATING URINARY TRACT INFECTIONS ticularly labdane, forskolin, and forskolin derivatives and USINGAGENTS THAT MIMIC OR ELEVATE analogs); agents that inhibit or block the activity of phos CYCLICAMP phodiesterases (PDE inhibitors); Toll-like receptor ligands; calcium channel activators or calcium activators; protein CROSS-REFERENCE TO RELATED kinase C (PKC) activators; and adenylate cyclase toxin. APPLICATIONS Exemplary agents that mimic cAMP include protein kinase A (PKA) activators. The methods may further include adminis 0001. This application is a continuation of U.S. patent tration of at least one cAMP elevator or agent that mimics application Ser. No. 12/663,959, filed Sep. 21, 2010, which is cAMP in combination with one or more additional active a national stage application of PCT/US2008/066647, filed compounds from other classes of therapeutic agents. In one Jun. 12, 2008, which claims the benefit of U.S. Provisional Such embodiment, the other class of therapeutic agents Patent Application Ser. No. 60/944,182, filed Jun. 15, 2007: includes any agent in use or in development to treat a UTI. the disclosures of which are incorporated herein by reference including antimicrobial agents such as, for example, antibi in their entirety. otics, and drugs that block bacterial adherence to the bladder wall. In another embodiment, the other class of therapeutic FEDERALLY SPONSORED RESEARCHOR agents includes cholesterol lowering drugs. DEVELOPMENT 0008 Compositions of the invention include pharmaceu 0002 This invention was made with government support tical compositions and kits for treating a UTI in a subject in under grant number R37 DK50814 awarded by the National need thereof. In some embodiments, the pharmaceutical com Institutes of Health. The United States government has cer positions and kits include therapeutically effective amounts tain rights in the invention. of at least two cAMP elevators or agents that mimic cAMP. and optionally one or more additional active compounds from FIELD OF THE INVENTION other classes of therapeutic agents. In other embodiments, the 0003. The presently disclosed subject matter relates to pharmaceutical compositions and kits include one or more methods and compositions to treat urinary tract infections cAMP elevator or agent that mimics cAMP in combination using agents that mimic or elevate intracellular levels of with at least one additional active compound from other cAMP. classes of therapeutic agents. BACKGROUND BRIEF DESCRIPTION OF THE DRAWINGS 0004 Urinary tract infections (UTIs) represent one of the 0009 FIG. 1 shows transmission electron micrographs of most common bacterial infections in humans. Each year at uropathogenic E. coli (UPEC) invading superficial bladder least 4 million patients (mostly women) seek treatment for epithelial cells (BECs) through fusiform canals. (A) Unin UTIs, and approximately $1.6 billion will be spent in the fected bladder epithelium showing scalloped plaques in the diagnosis and treatment of UTIS. Frequent recurrences in lumenal surface as well as in intracellular fusiform vesicles healthy adult females after an initial bout of UTI continue to (scale bars-2 um).
Load more

Recommended publications
  • The Single Cyclic Nucleotide-Specific Phosphodiesterase of the Intestinal Parasite Giardia Lamblia Represents a Potential Drug Target
    RESEARCH ARTICLE The single cyclic nucleotide-specific phosphodiesterase of the intestinal parasite Giardia lamblia represents a potential drug target Stefan Kunz1,2*, Vreni Balmer1, Geert Jan Sterk2, Michael P. Pollastri3, Rob Leurs2, Norbert MuÈ ller1, Andrew Hemphill1, Cornelia Spycher1¤ a1111111111 1 Institute of Parasitology, Vetsuisse Faculty, University of Bern, Bern, Switzerland, 2 Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute of Molecules, Medicines and Systems (AIMMS), Vrije a1111111111 Universiteit Amsterdam, Amsterdam, The Netherlands, 3 Department of Chemistry and Chemical Biology, a1111111111 Northeastern University, Boston, Massachusetts, United States of America a1111111111 a1111111111 ¤ Current address: Euresearch, Head Office Bern, Bern, Switzerland * [email protected] Abstract OPEN ACCESS Citation: Kunz S, Balmer V, Sterk GJ, Pollastri MP, Leurs R, MuÈller N, et al. (2017) The single cyclic Background nucleotide-specific phosphodiesterase of the Giardiasis is an intestinal infection correlated with poverty and poor drinking water quality, intestinal parasite Giardia lamblia represents a potential drug target. PLoS Negl Trop Dis 11(9): and treatment options are limited. According to the Center for Disease Control and Preven- e0005891. https://doi.org/10.1371/journal. tion, Giardia infections afflict nearly 33% of people in developing countries, and 2% of the pntd.0005891 adult population in the developed world. This study describes the single cyclic nucleotide- Editor: Aaron R. Jex, University of Melbourne, specific phosphodiesterase (PDE) of G. lamblia and assesses PDE inhibitors as a new gen- AUSTRALIA eration of anti-giardial drugs. Received: December 5, 2016 Accepted: August 21, 2017 Methods Published: September 15, 2017 An extensive search of the Giardia genome database identified a single gene coding for a class I PDE, GlPDE.
    [Show full text]
  • Signal Transduction Guide
    Signal Transduction Product Guide | 2007 NEW! Selective T-type Ca2+ channel blockers, NNC 55-0396 and Mibefradil ZM 447439 – Novel Aurora Kinase Inhibitor NEW! Antibodies for Cancer Research EGFR-Kinase Selective Inhibitors – BIBX 1382 and BIBU 1361 DRIVING RESEARCH FURTHER Calcium Signaling Agents ...................................2 G Protein Reagents ...........................................12 Cell Cycle and Apoptosis Reagents .....................3 Ion Channel Modulators ...................................13 Cyclic Nucleotide Related Tools ...........................7 Lipid Signaling Agents ......................................17 Cytokine Signaling Agents ..................................9 Nitric Oxide Tools .............................................19 Enzyme Inhibitors/Substrates/Activators ..............9 Protein Kinase Reagents....................................22 Glycobiology Agents .........................................12 Protein Phosphatase Reagents ..........................33 Neurochemicals | Signal Transduction Agents | Peptides | Biochemicals Signal Transduction Product Guide Calcium Signaling Agents ......................................................................................................................2 Calcium Binding Protein Modulators ...................................................................................................2 Calcium ATPase Modulators .................................................................................................................2 Calcium Sensitive Protease
    [Show full text]
  • Analyses of PDE-Regulated Phosphoproteomes Reveal Unique and Specific Camp-Signaling Modules in T Cells
    Analyses of PDE-regulated phosphoproteomes reveal unique and specific cAMP-signaling modules in T cells Michael-Claude G. Beltejara, Ho-Tak Laua, Martin G. Golkowskia, Shao-En Onga, and Joseph A. Beavoa,1 aDepartment of Pharmacology, University of Washington, Seattle, WA 98195 Contributed by Joseph A. Beavo, May 28, 2017 (sent for review March 10, 2017; reviewed by Paul M. Epstein, Donald H. Maurice, and Kjetil Tasken) Specific functions for different cyclic nucleotide phosphodiester- to bias T-helper polarization toward Th2, Treg, or Th17 pheno- ases (PDEs) have not yet been identified in most cell types. types (13, 14). In a few cases increased cAMP may even potentiate Conventional approaches to study PDE function typically rely on the T-cell activation signal (15), particularly at early stages of measurements of global cAMP, general increases in cAMP- activation. Recent MS-based proteomic studies have been useful dependent protein kinase (PKA), or the activity of exchange in characterizing changes in the phosphoproteome of T cells under protein activated by cAMP (EPAC). Although newer approaches various stimuli such as T-cell receptor stimulation (16), prosta- using subcellularly targeted FRET reporter sensors have helped glandin signaling (17), and oxidative stress (18), so much of the define more compartmentalized regulation of cAMP, PKA, and total Jurkat phosphoproteome is known. Until now, however, no EPAC, they have limited ability to link this regulation to down- information on the regulation of phosphopeptides by PDEs has stream effector molecules and biological functions. To address this been available in these cells. problem, we have begun to use an unbiased mass spectrometry- Inhibitors of cAMP PDEs are useful tools to study PKA/EPAC- based approach coupled with treatment using PDE isozyme- mediated signaling, and selective inhibitors for each of the 11 PDE – selective inhibitors to characterize the phosphoproteomes of the families have been developed (19 21).
    [Show full text]
  • Phosphodiesterase (PDE)
    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
    [Show full text]
  • Inhibitors of Cyclic Nucleotide Phosphodiesterase Isozymes Type-III and Type-IV Suppress Mitogenesis of Rat Mesangial Cells
    Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells. K Matousovic, … , E N Chini, T P Dousa J Clin Invest. 1995;96(1):401-410. https://doi.org/10.1172/JCI118049. Research Article We studied interactions between the mitogen-activated protein kinase (MAPK) signalling pathway and cAMP-protein kinase (PKA) signaling pathway in regulation of mitogenesis of mesangial cells (MC) determined by [3H]thymidine incorporation, with or without added EGF. Forskolin or dibutyryl cAMP strongly (by 60-70%) inhibited [3H]thymidine incorporation into MC. Cilostamide, lixazinone or cilostazol selective inhibitors of cAMP-phosphodiesterase (PDE) isozyme PDE-III, inhibited mitogenesis to similar extent as forskolin and DBcAMP and activated in situ PKA, but without detectable increase in cAMP levels. Cilostamide and cilostazol were more than three times more effective at inhibiting mesangial mitogenesis than rolipram and denbufylline, inhibitors of isozyme PDE-IV, even though PDE-IV was two times more abundant in MC than was PDE-III. On the other hand, when incubated with forskolin, rolipram-enhanced cAMP accumulation was far greater (10-100x) than with cilostamide. EGF increased MAPK activity (+300%); PDE isozyme inhibitors which suppressed mitogenesis also inhibited MAPK. PDE isozyme inhibitors also suppressed PDGF-stimulated MC proliferation. We conclude that cAMP inhibits the mitogen-dependent MAPK-signaling pathway probably by decreasing the activity of Raf-1 due to PKA-catalyzed phosphorylation. Further, we surmise that minor increase in the cAMP pool metabolized by PDE-III is intimately related to regulation of mesangial proliferation. Thus, PDE isozyme inhibitors have the potential to suppress MC proliferation by a focused effect upon signaling pathways.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Can PDE Inhibition Improve Cognition? : Translational Insights
    Can PDE inhibition improve cognition? : Translational insights Citation for published version (APA): Reneerkens, O. A. H. (2013). Can PDE inhibition improve cognition? : Translational insights. Maastricht University. https://doi.org/10.26481/dis.20130418or Document status and date: Published: 01/01/2013 DOI: 10.26481/dis.20130418or Document Version: Publisher's PDF, also known as Version of record Please check the document version of this publication: • A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website. • The final author version and the galley proof are versions of the publication after peer review. • The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal. If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement: www.umlib.nl/taverne-license Take down policy If you believe that this document breaches copyright please contact us at: [email protected] providing details and we will investigate your claim.
    [Show full text]
  • Phosphodiesterase Inhibitors: Their Role and Implications
    International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.1, No.4, pp 1148-1160, Oct-Dec 2009 PHOSPHODIESTERASE INHIBITORS: THEIR ROLE AND IMPLICATIONS Rumi Ghosh*1, Onkar Sawant 1, Priya Ganpathy1, Shweta Pitre1 and V.J.Kadam1 1Dept. of Pharmacology ,Bharati Vidyapeeth’s College of Pharmacy, University of Mumbai, Sector 8, CBD Belapur, Navi Mumbai -400614, India. *Corres.author: rumi 1968@ hotmail.com ABSTRACT: Phosphodiesterase (PDE) isoenzymes catalyze the inactivation of intracellular mediators of signal transduction such as cAMP and cGMP and thus have pivotal roles in cellular functions. PDE inhibitors such as theophylline have been employed as anti-asthmatics since decades and numerous novel selective PDE inhibitors are currently being investigated for the treatment of diseases such as Alzheimer’s disease, erectile dysfunction and many others. This review attempts to elucidate the pharmacology, applications and recent developments in research on PDE inhibitors as pharmacological agents. Keywords: Phosphodiesterases, Phosphodiesterase inhibitors. INTRODUCTION Alzheimer’s disease, COPD and other aliments. By cAMP and cGMP are intracellular second messengers inhibiting specifically the up-regulated PDE isozyme(s) involved in the transduction of various physiologic with newly synthesized potent and isoezyme selective stimuli and regulation of multiple physiological PDE inhibitors, it may possible to restore normal processes, including vascular resistance, cardiac output, intracellular signaling selectively, providing therapy with visceral motility, immune response (1), inflammation (2), reduced adverse effects (9). neuroplasticity, vision (3), and reproduction (4). Intracellular levels of these cyclic nucleotide second AN OVERVIEW OF THE PHOSPHODIESTERASE messengers are regulated predominantly by the complex SUPER FAMILY superfamily of cyclic nucleotide phosphodiesterase The PDE super family is large, complex and represents (PDE) enzymes.
    [Show full text]
  • Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
    International Journal of Molecular Sciences Review Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19? Mauro Giorgi 1,*, Silvia Cardarelli 2, Federica Ragusa 3, Michele Saliola 1, Stefano Biagioni 1, Giancarlo Poiana 1 , Fabio Naro 2 and Mara Massimi 3,* 1 Department of Biology and Biotechnology “Charles Darwin”, Sapienza University of Rome, 00185 Rome, Italy; [email protected] (M.S.); [email protected] (S.B.); [email protected] (G.P.) 2 Department of Anatomical, Histological, Forensic Medicine and Orthopedic Sciences, Sapienza University, 00185 Rome, Italy; [email protected] (S.C.); [email protected] (F.N.) 3 Department of Life, Health and Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy; [email protected] * Correspondence: [email protected] (M.G.); [email protected] (M.M.) Received: 10 July 2020; Accepted: 24 July 2020; Published: 27 July 2020 Abstract: In March 2020, the World Health Organization declared the severe acute respiratory syndrome corona virus 2 (SARS-CoV2) infection to be a pandemic disease. SARS-CoV2 was first identified in China and, despite the restrictive measures adopted, the epidemic has spread globally, becoming a pandemic in a very short time. Though there is growing knowledge of the SARS-CoV2 infection and its clinical manifestations, an effective cure to limit its acute symptoms and its severe complications has not yet been found. Given the worldwide health and economic emergency issues accompanying this pandemic, there is an absolute urgency to identify effective treatments and reduce the post infection outcomes. In this context, phosphodiesterases (PDEs), evolutionarily conserved cyclic nucleotide (cAMP/cGMP) hydrolyzing enzymes, could emerge as new potential targets.
    [Show full text]
  • Various Subtypes of Phosphodiesterase Inhibitors Differentially Regulate Pulmonary Vein and Sinoatrial Node Electrical Activities
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 19: 2773-2782, 2020 Various subtypes of phosphodiesterase inhibitors differentially regulate pulmonary vein and sinoatrial node electrical activities YUNG‑KUO LIN1,2*, CHEN‑CHUAN CHENG3*, JEN‑HUNG HUANG1,2, YI-ANN CHEN4, YEN-YU LU5, YAO‑CHANG CHEN6, SHIH‑ANN CHEN7 and YI-JEN CHEN1,8 1Department of Internal Medicine, Division of Cardiovascular Medicine, Wan Fang Hospital; 2Department of Internal Medicine, Division of Cardiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11696; 3Division of Cardiology, Chi‑Mei Medical Center, Tainan 71004; 4Division of Nephrology; 5Division of Cardiology, Department of Internal Medicine, Sijhih Cathay General Hospital, New Taipei 22174; 6Department of Biomedical Engineering, National Defense Medical Center, Taipei 11490; 7Heart Rhythm Center and Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217; 8Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11696, Taiwan, R.O.C. Received May 16, 2019; Accepted January 9, 2020 DOI: 10.3892/etm.2020.8495 Abstract. Phosphodiesterase (PDE)3-5 are expressed in 20.7±4.6%, respectively. In addition, milrinone (1 and 10 µM) cardiac tissue and play critical roles in the pathogenesis of induced the occurrence of triggered activity (0/8 vs. 5/8; heart failure and atrial fibrillation. PDE inhibitors are widely P<0.005) in PVs. Rolipram increased PV spontaneous activity used in the clinic, but their effects on the electrical activity by 7.5±1.3‑9.5±4.0%, although this was not significant, and did of the heart are not well understood. The aim of the present not alter SAN spontaneous activity.
    [Show full text]
  • Metabolic Enzyme/Protease
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com Metabolic Enzyme/Protease Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of natural product small molecules within a cell or tissue. In each pathway, enzymes catalyze the conversion of substrates into structurally similar products. Metabolic processes typically transform small molecules, but also include macromolecular processes such as DNA repair and replication, and protein synthesis and degradation. Metabolism maintains the living state of the cells and the organism. Proteases are used throughout an organism for various metabolic processes. Proteases control a great variety of physiological processes that are critical for life, including the immune response, cell cycle, cell death, wound healing, food digestion, and protein and organelle recycling. On the basis of the type of the key amino acid in the active site of the protease and the mechanism of peptide bond cleavage, proteases can be classified into six groups: cysteine, serine, threonine, glutamic acid, aspartate proteases, as well as matrix metalloproteases. Proteases can not only activate proteins such as cytokines, or inactivate them such as numerous repair proteins during apoptosis, but also expose cryptic sites, such as occurs with β-secretase during amyloid precursor protein processing, shed various transmembrane proteins such as occurs with metalloproteases and cysteine proteases, or convert receptor agonists into antagonists and vice versa such as chemokine conversions carried out by metalloproteases, dipeptidyl peptidase IV and some cathepsins. In addition to the catalytic domains, a great number of proteases contain numerous additional domains or modules that substantially increase the complexity of their functions.
    [Show full text]
  • Phosphodiesterases, 3',5'-Cyclic Nucleotide (Pdes) (Version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
    IUPHAR/BPS Guide to Pharmacology CITE https://doi.org/10.2218/gtopdb/F260/2019.4 Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs) (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database Chen Yan1 1. University of Rochester, USA Abstract 3',5'-Cyclic nucleotide phosphodiesterases (PDEs, 3',5'-cyclic-nucleotide 5'-nucleotidohydrolase), E.C. 3.1.4.17, catalyse the hydrolysis of a 3',5'-cyclic nucleotide (usually cyclic AMP or cyclic GMP). isobutylmethylxanthine is a nonselective inhibitor with an IC50 value in the millimolar range for all isoforms except PDE 8A, 8B and 9A. A 2',3'-cyclic nucleotide 3'-phosphodiesterase (E.C. 3.1.4.37 CNPase) activity is associated with myelin formation in the development of the CNS. Contents This is a citation summary for Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs) in the Guide to Pharmacology database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links. GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts. Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed.
    [Show full text]